If you have been reading about lyophilisation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-28. Numbers and descriptions here follow the published literature rather than marketing material.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
== Synthesis of GnSAF == GnSAF is produced in the granulosa cells of the small sized antral follicles, which have the highest concentration of GnSAF. Concentrations of GnSAF bioactivity is inversely proportional to follicle size. Upon synthesis, GnSAF is released into peripheral circulation. Follicle-stimulating hormone (FSH) from the anterior pituitary stimulates and prolongs GnSAF biosynthesis in growing small antral follicles in the ovary. FSH induces expression and transcription of exons 12 and 13 of the HSA gene found in granulosa cells. During the early and mid-follicular phase, FSH is secreted to promote growth and proliferation of the granulosa cells, which increases GnSAF concentrations. Once the dominant ovarian follicle has been selected at mid-follicular phase, the non-dominant follicles undergo atresia. Without the presence of small follicles during the late follicular phase, GnSAF concentrations steadily decline to its lowest levels observable in the ovarian cycle. Additionally, the rate of GnSAF biosynthesis by the granulosa cells of the remaining dominant follicle decreases as the follicle approaches maturation. During the transition between luteal phase and follicular phase, GnSAF gradually increases from the late luteal phase and onwards due to the recruitment of follicles and concomitant rise of FSH. The time-course production of GnSAF depends on the serum FSH concentrations. Higher serum concentrations of FSH increases the potency of the attenuating effects of GnSAF on release of LH.
== Epidemiology == As of December 2023, most people who acquire this disease are between the ages of two and six years old, living in the poorest countries of the world. Accurate figures for noma prevalence are not available due to difficulties in diagnosis and reporting in the endemic areas. In 1998, the World Health Organization estimated that 140,000 new cases were occurring each year, with a 90% fatality rate, and a total of 770,000 surviving with scarring or disfigurement. Noma is associated with a very high morbidity, and a mortality rate of approximately 90 percent. The prognosis is much better with treatment; if children have access to medical care, the mortality rate drops to under 10 percent. After gangrene sets in, patients are likely to die of sepsis within one to two weeks.
The volunteer distributed computing project Folding@home simulates protein folding. It was used for medical research. In March 2020 it became the world's first system to reach one exaFLOPS and reached approximately 2.43 x86 exaFLOPS by 13 April 2020 – many times faster than Summit, the fastest supercomputer of that time. That month Rosetta@home joined the effort. Researchers announced that Rosetta@home allowed them to "accurately predict the atomic-scale structure of an important coronavirus protein weeks before it could be measured in the lab." In May 2020, the OpenPandemics—COVID-19 partnership was launched between Scripps Research and IBM's World Community Grid. The partnership is a distributed computing project that "will automatically run a simulated experiment in the background [of connected home PCs] that will help predict the efficacy of a particular chemical compound as a potential treatment for COVID-19."
=== Electronic spectrum === Electrons propagating through the graphene honeycomb lattice effectively lose their mass, producing quasi-particles described by a 2D analogue of the Dirac equation rather than the Schrödinger equation for spin-1/2 particles.
== Education == Frank completed her M.D. and Ph.D. in biochemistry at the University of Pennsylvania. She completed a clinical pathology residency at the Brigham and Women's Hospital. During her postdoctoral research fellowship in immunology, she focused on V(D)J recombination in developing lymphocytes in the Howard Hughes Medical Institute laboratory of Frederick Alt at the Boston Children's Hospital. As a faculty member, her studies included DNA repair mechanisms relevant to both cancer and immunology, followed by microbiological investigations of Staphylococcus aureus and enterobacteriaceae.
Sources: en.wikipedia.org
=== BrMASS Manuel Riveros Medal === 2024 Livia S. Eberlin, Debora Azevedo 2022 Lidija Nikolaevna Gall, Julia Laskin, Claudia Moraes de Rezende, Rosa Erra-Balsells Maria Fernanda Georgina Gine Rosias Conchetta Cacheres
Commission B1: Thermodynamics and Transfer Processes The objectives of Commission B1 on Thermodynamics and Transfer Processes are to provide academic and industrial information and data, and to propose any solutions on thermodynamics and transfer processes. The Commission B1 has been extremely active in IIR Working Groups, sub-commissions, IIR conferences, co-sponsored conferences, and commission business meetings. As well as being involved in IIR Working Groups on the mitigation of direct emissions of greenhouse gases in refrigeration, the commission is equally involved in the Working Group on Life Cycle Climate Performance (LCCP) Evaluation. Active in IIR conferences and congresses, Commission B1 similarly organises workshops in various fields such as refrigerant charge reduction in refrigerating systems. Initiatives and opportunities, such as the phase-down of high-GWP refrigerants, energy-efficient buildings and cars, transport refrigeration, food preservation, the economic importance of the refrigeration sector, the involvement of the younger generation and identifying industrial needs are all at the heart of Commission B1.
==== Invasion of Iraq ==== Planning for the Operation Iraqi Freedom began in December 2001; in 2002 several teams of 10th SFG and CIA SAD operatives were infiltrated into Iraqi Kurdistan in advance of hostilities. They were based in the Harir valley outside Irbil and tasked to develop ground truth intelligence while organising and training the Peshmerga; they were also there to monitor Ansar al-Islam and plan for a future operation against them. For the 2003 invasion of Iraq, CJSOTF-West (Combined Joint Special Operations Task Force-West/Task Force Dagger) was formed around the 5th SFG, their ODAs were tasked with two core missions: the first – to counter the SCUD TELs and by denying the Iraqi military the use of potential launch sites and the second – provide both intelligence-gathering and screening function in support of conventional forces to build up an accurate picture of Iraqi force dispositions in western Iraq. The Green Beret ODAs were deployed under the command and control of ODBs (Operational Detachment Bravo) which operated as roving AOBs (Advanced Operating Bases), these AOBs provided a mobile resupply function using their modified M1078 Light Medium Transport Vehicles which meant that the ODA patrols could operate for extended periods in enemy territory before linking up with a fighting patrol that would be escorting the AOBs for combat resupply.
Periostin (POSTN, PN, or osteoblast-specific factor OSF-2) is a protein that in humans is encoded by the POSTN gene. Periostin functions as a ligand for alpha-V/beta-3 and alpha-V/beta-5 integrins to support adhesion and migration of epithelial cells. Periostin is a gla domain vitamin K dependent factor.
Sources: en.wikipedia.org
== Awards == Faculty Volunteer Service Award, University of Arkansas Outstanding Service Award, Veterans Association (1989-2005) Distinguished Faculty Award, University of Arkansas (1992) Distinguished Service Award, American Association of Tissue Banks (1994) Senior Arkansans Hall of Fame (1995) Silver Beaver Award, Boy Scouts of American (1998) Distinguished Alumni Award, University of Iowa (2006)
The major long-term complications of diabetes relate to damage to blood vessels at both macrovascular and microvascular levels. Diabetes doubles the risk of cardiovascular disease, and about 75% of deaths in people with diabetes are due to coronary artery disease. Other macrovascular morbidities include stroke and peripheral artery disease. Microvascular disease affects the eyes, kidneys, and nerves. Damage to the retina, known as diabetic retinopathy, is the most common cause of blindness in people of working age. The eyes can also be affected in other ways, including development of cataract and glaucoma. It is recommended that people with diabetes visit an optometrist or ophthalmologist once a year. Diabetic nephropathy is a major cause of chronic kidney disease, accounting for over 50% of patients on dialysis in the United States. Diabetic neuropathy, damage to nerves, manifests in various ways, including sensory loss, neuropathic pain, and autonomic dysfunction (such as postural hypotension, diarrhea, and erectile dysfunction). Loss of pain sensation predisposes to trauma that can lead to diabetic foot problems (such as ulceration), the most common cause of non-traumatic lower-limb amputation. Hearing loss is another long-term complication associated with diabetes. Based on extensive data and numerous cases of gallstone disease, it appears that a causal link might exist between type 2 diabetes and gallstones. People with diabetes are at a higher risk of developing gallstones compared to those without diabetes.
Arranging a secret deal in which Tippett would be traded to a club of his choice at the end of 2012 Direct payments of $100,000 outside the salary cap in each of 2011 and 2012 Illegally arranging third-party deals in 2011 and 2012, resulting in Tippett receiving further money outside the salary cap in those years. Adelaide was considered likely to incur a loss of draft picks, among other penalties, if found guilty, but the AFL Commission was yet to complete its hearing into the matter when the National Draft was held on 22 November 2012, so the club was permitted to participate in the draft as normal. However, on the day before the draft, the club voluntarily relinquished its highest two remaining selections (No. 20 and 54) as a "gesture of goodwill" ahead of the hearing. The final hearing took place on 30 November, and Adelaide and Tippett pleaded guilty to all charges. Adelaide was stripped of its first and second round draft picks, and banned from taking any father-son selections, in the 2013 National Draft, and received a $300,000 fine. Tippett was suspended for the 2013 NAB Cup and 11 premiership matches, with a further suspended sentence of 11 matches, and received a $50,000 fine. Several senior Adelaide personnel were also punished by the league: chief executive Steven Trigg and former football manager John Reid were each fined $50,000 and banned from AFL functions for six months (with a further suspended sentence of six months), and current football manager Phil Harper was banned from AFL functions for two months with a four-month suspended sentence.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.